Blocking METTL14 Slows Vascular Aging by Silencing a Key Inflammation Switch
Deleting the RNA methylation enzyme METTL14 in blood vessel cells reduces arterial stiffness, inflammation, and cellular senescence in mice and human cells.
Summary
Researchers at Harbin Medical University discovered that METTL14, an RNA methylation enzyme, drives vascular aging by chemically modifying and stabilizing TLR4 mRNA—a master inflammation trigger—in arterial endothelial cells. METTL14 levels were elevated in aged mice, aged humans, and senescent endothelial cells. Deleting or knocking down METTL14 specifically in endothelial cells reduced arterial stiffness, arterial wall remodeling, oxidative stress, and cellular senescence in multiple mouse models. Conversely, overexpressing METTL14 worsened these aging markers. Blood levels of both METTL14 and TLR4 correlated positively with atherosclerosis and arteriosclerosis severity in human patients, suggesting METTL14 inhibition as a potential therapeutic strategy against vascular aging and related cardiovascular disease.
Detailed Summary
Vascular aging—characterized by arterial stiffness, endothelial senescence, and chronic low-grade inflammation—is a major driver of cardiovascular disease in older adults. Despite its clinical importance, the upstream molecular regulators that initiate and sustain vascular inflammation during aging remain poorly understood. This study identifies METTL14, a core component of the N6-methyladenosine (m6A) RNA methyltransferase complex, as a critical promoter of vascular aging through its regulation of Toll-like receptor 4 (TLR4) mRNA stability.
The research team used three complementary aging models: naturally aged mice, D-galactose-induced accelerated aging mice, and endothelial cell-specific METTL14 knockout (EC-METTL14-KO) mice. They also studied senescent human umbilical vein endothelial cells (HUVECs), human aortic endothelial cells (HAECs), and mouse aortic endothelial cells (MAECs). In all systems, METTL14 expression was significantly upregulated in aged or senescent endothelial cells compared to young controls. Crucially, endothelium-specific METTL14 deletion markedly reduced arterial stiffness (measured by pulse wave velocity), attenuated arterial wall remodeling, and suppressed endothelial senescence markers including p21, p16, and SA-β-galactosidase activity. Endothelium-specific METTL14 overexpression produced the opposite effects, accelerating aging phenotypes.
Mechanistically, the team demonstrated that METTL14 deposits m6A marks on TLR4 mRNA, enhancing its stability and thus increasing TLR4 protein levels. Elevated TLR4 then activates downstream NF-κB inflammatory signaling, driving the senescence-associated secretory phenotype (SASP), oxidative stress, and endothelial dysfunction. Knockdown of TLR4 reversed the pro-aging effects of METTL14 overexpression, confirming the METTL14→m6A-TLR4→NF-κB axis as the operative pathway. MeRIP-seq (methylated RNA immunoprecipitation sequencing) and RNA stability assays provided direct molecular evidence for m6A-dependent TLR4 mRNA stabilization.
In a human clinical cohort, blood METTL14 and TLR4 levels positively correlated with markers of atherosclerosis and arteriosclerosis, lending translational weight to the experimental findings. Patients with more advanced vascular disease showed higher circulating levels of both proteins, suggesting these molecules may serve as biomarkers as well as therapeutic targets.
The study positions METTL14 as an epitranscriptomic amplifier of vascular inflammation and aging, and proposes that targeted METTL14 knockdown—potentially via RNA interference or small-molecule inhibitors—could represent a novel strategy to slow vascular aging and reduce cardiovascular risk in older populations.
Key Findings
- METTL14 is upregulated in aortic endothelial cells of aged mice, aged humans, and senescent endothelial cells.
- Endothelium-specific METTL14 deletion reduces arterial stiffness, wall remodeling, and endothelial senescence in mice.
- METTL14 stabilizes TLR4 mRNA via m6A modification, activating NF-κB-driven vascular inflammation.
- TLR4 knockdown reverses the pro-aging effects caused by METTL14 overexpression in endothelial cells.
- Blood METTL14 and TLR4 levels positively correlate with atherosclerosis and arteriosclerosis severity in humans.
Methodology
The study used natural aging and D-galactose-induced mouse models alongside endothelial cell-specific METTL14 knockout and overexpression mice. In vitro experiments employed senescent HUVECs, HAECs, and MAECs; MeRIP-seq and RNA stability assays confirmed m6A-mediated TLR4 mRNA regulation. A human clinical cohort provided correlational data linking blood METTL14/TLR4 levels to vascular disease severity.
Study Limitations
The human data are correlational and cannot establish causality between METTL14/TLR4 levels and vascular disease outcomes. The study focuses exclusively on endothelial cells, leaving open whether METTL14 in vascular smooth muscle or immune cells also contributes to vascular aging. Long-term safety and specificity of METTL14 inhibition in vivo have not yet been evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.